Biliary atresia treatment market
Biliary Atresia Treatment Market, by Disease Type (Type I, Type II, and Type III), by Treatment Type (Medications (Bile Acids, Antibiotics, and Corticosteroids) and Surgery), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
- Nov 2021
- CMI4779
- 191 Pages
- Excel & Pdf
- Pharmaceutical
Biliary atresia is a rare condition which majorly occurs in infants. In this condition, the bile ducts that transport bile from the liver to the gall bladder are blocked. The symptoms of this disease appear about two to eight weeks after birth. Symptoms of the biliary atresia include jaundice, pale colored stools, slow or no weight gain, dark urine, and an enlarged spleen. Once biliary atresia is suspected, a surgery called Kasai portoenterostomy needs to be performed, as early operation is more likely to be successful. If the Kasai operation fails, liver transplantation may be needed.
The global biliary atresia treatment market is estimated to be valued at US$ 910.7 million in 2021 and is expected to exhibit a CAGR of 7.7% during the forecast period (2021-2028).
Figure 1. Global Biliary Atresia Treatment Market Share (%) in Terms of Value, by Disease Type, 2021
The increasing prevalence of biliary atresia and its surgery is expected to drive the market growth during the forecast period.
The increasing incidence of biliary atresia and its surgery is expected to drive the market growth during the forecast period. For instance, according to an article published by Research Gate in March 2016, babies born with biliary atresia during 1997 to 2010 were identified from the Taiwan National Health Insurance Research Database. Moreover, among 513 total biliary atresia cases, about 457 (89%) cases underwent the surgery (Kasai procedure).
Biliary Atresia Treatment Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2020 | Market Size in 2021: | US$ 910.7 Mn |
Historical Data for: | 2017 to 2020 | Forecast Period: | 2021 to 2028 |
Forecast Period 2021 to 2028 CAGR: | 7.7% | 2028 Value Projection: | US$ 1,527.9 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
AstraZeneca plc, Eisai Co., Ltd., Mirum Pharmaceuticals, Inc., Pfizer Inc., Albireo Pharma, Inc., Novartis AG, Alkem Labs, and Glenmark Pharmaceuticals |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Figure 2.Global Biliary Atresia Treatment Market Share (%), by Treatment Type, 2021
Increasing advancements in laboratory screening and diagnosis of biliary atresia is expected to drive the market growth during the forecast period.
The increasing advancements in laboratory screening and diagnosis of biliary atresia by researchers and key players are expected to drive the biliary atresia treatment market growth during the forecast period. For instance, according to an article published in the journal ‘Digestive Medical Research’ in September 2021, recent advancements in non-invasive molecular markers, such as gamma-glutamyl transpeptidase (GGT), matrix metalloproteinase-7 (MMP7), interleukin-33 (IL-33), and stool proteomics showed promising results as effective diagnostic markers in biliary atresia.
Global Biliary Atresia Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
Due to the COVID-19 pandemic, pediatric liver research has faced a lot of challenges. The most impacted have been clinical research studies focusing on rare diseases like biliary atresia (BA), which is the most common indication for liver transplantation.
Biliary atresia studies done under the ‘The Childhood Liver Disease Research Network’ (ChiLDReN), an NIH-funded consortium and biorepository, has been largely interrupted during this COVID-19 pandemic, as there has been no new sample collection. Due to the failure to capture new cases of BA, the timeline of research progress will certainly be prolonged. Moreover, the diagnosis of BA has been delayed, as parents are scared of bringing their infants to their pediatrician’s hospital during this period for BA diagnosis.
As several pediatric liver diseases fall under the category of rare diseases, the unstable economic times and greatest impact of this pandemic on funding of pediatric liver research may be seen.
Global Biliary Atresia Treatment Market: Restraint
The major factors that hinder the growth of the global biliary atresia treatment market include safety concerns related to the drug, higher cost involved in the treatment, limited treatment options, and lack of skilled professional in some developing countries like India, Kenya and others.
Key Players
Major players operating in the global biliary atresia treatment market include AstraZeneca plc, Eisai Co., Ltd., Mirum Pharmaceuticals, Inc., Pfizer Inc., Albireo Pharma, Inc., Novartis AG, Alkem Labs, and Glenmark Pharmaceuticals
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Disease Type
- Market Snapshot, By Treatment Type
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches / Approvals
- Pipeline analysis
- Reimbursement Scenario
- PEST Analysis
- PORTER’s Analysis
- Merger, Collaboration and Acquisitions Scenario
- Market Dynamics
- Global Biliary Atresia Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply side and Demand Side Analysis
- Economic Impart
- Global Biliary Atresia Treatment Market, By Disease Type, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Type I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Type II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Type III
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Introduction
- Global Biliary Atresia Treatment Market, By Treatment Type, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Bile Acids
- Antibiotics
- Corticosteroids
- Surgery
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- Global Biliary Atresia Treatment Market, By Region, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2028
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Region/Country, 2017 – 2028, (US$ Mn)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mirum Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Albireo Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alkem Labs.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca plc
- Analyst Views
- Section
- Research Methodology
- About us
*Browse 28 market data tables and 24 figures on "Biliary Atresia Treatment Market” - Global forecast to 2028